[Biomarker indicators of chemoprevention among subjects occupationally exposed to metals].
Chemoprevention with chelating agent Humetta for three months was performed, due to anaemia and other haematologic disorders, immunotoxicological alterations and/or increased chromosome aberration rate among galvanisers and goldsmiths occupationally exposed to precious and heavy metals. Twenty-two of altogether 47 subjects took part voluntarily in the chemoprevention, and the rest of the subjects served as untreated controls. Complex clinical laboratory testing including detailed anamneses; genotoxicological and immunotoxicological monitoring were performed before and after administration of chemopreventive agent. After chemoprevention a significant improvement was observed in anaemia and serum glucose levels, while a less marked improvement was found in serum cholesterol levels and liver functions. Altered chromosome aberration and apoptotic cell fraction also tended to normalise after treatment. Immunological parameters were not affected by the treatment. The obtained results may suggest that chemoprevention with chelating agents as Humetta can help in the prevention of harmful effects of occupational exposures to metals.
Major
Jenô
J
Országos Kémiai Biztonsági Intézet, Fodor József Országos Közegészségügyi Központ, Budapest, 1450, Hungary. majorj.okbi@okk.antsz.hu
Jakab
Mátyás
M
Biró
Anna
A
Klupp
Tibor
T
Magyar
Balázs
B
Gál
Katalin
K
Oláh
Gábor
G
Fodor
Zoltán
Z
Tompa
Anna
A
D015415:Biomarkers / Q000097:blood; D002614:Chelating Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002869:Chromosome Aberrations / Q000139:chemically induced; D004249:DNA Damage / Q000187:drug effects / Q000276:immunology; D005260:Female; D006402:Hematologic Diseases / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D008213:Lymphocyte Activation; D016131:Lymphocyte Subsets; D008297:Male; D019216:Metals, Heavy / Q000009:adverse effects*; D008875:Middle Aged; D009152:Mutagenicity Tests / Q000379:methods; D009153:Mutagens / Q000009:adverse effects*; D009784:Occupational Diseases / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*; D016273:Occupational Exposure / Q000009:adverse effects; D012907:Smoking / Q000009:adverse effects; D016896:Treatment Outcome
D015415:Biomarkers; D002614:Chelating Agents; D019216:Metals, Heavy; D009153:Mutagens